key: cord-0958128-0z7ey1nm
authors: Calusic, Martina; Marcec, Robert; Luksa, Lea; Jurkovic, Ivan; Kovac, Natasa; Mihaljevic, Slobodan; Likic, Robert
title: Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
date: 2021-12-01
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15126
sha: e7f98e418e7abcf6e8fef6d7488da34896bb8fd0
doc_id: 958128
cord_uid: 0z7ey1nm

AIMS: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma‐1 receptor agonist, has so far shown promise in the prevention of COVID‐19 progression as an early treatment option in three trials. The aim of this study was to evaluate the safety and efficacy of fluvoxamine in COVID‐19 patients if administered later in the course of the disease. METHODS: The study was designed as an open‐label, prospective cohort trial with matched controls. In April and May 2021, 51 ICU COVID‐19 patients hospitalised in the University Hospital Dubrava and University Hospital Centre Zagreb, Croatia, were treated with fluvoxamine 100 mg three times daily for 15 days in addition to standard therapy and they were prospectively matched for age, gender, vaccination against COVID‐19, disease severity and comorbidities with 51 ICU controls. RESULTS: No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU or total hospital stay. However, overall mortality was lower in the fluvoxamine group, 58.8% (n = 30/51), than in the control group, 76.5% (n = 39/51), HR 0.58, 95% CI (0.36–0.94, P = .027). CONCLUSION: Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID‐19 patients could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID‐19 patients are urgently required.

The authors confirm that the Principal Investigator for this paper is Martina Calusic, MD and that she had direct clinical responsibility for the patients. time these new compounds successfully pass clinical trials and reach the market as new pharmacological entities, their price and low availability will once again limit worldwide use and broaden inequalities between the poor and the rich countries. Therefore, since the start of the pandemic, the repurposing of already existing and approved drugs for COVID-19 has been deemed a worthwhile approach.

Many potential drugs have already been tested for repurposing against COVID-19, but the results of such trials have mostly been disappointing. The WHO Solidarity Trial interim results showed that hydroxychloroquine, lopinavir, remdesivir and interferon beta-1a had no impact on mortality, hospitalisation duration or initiation of ventilation support in COVID-19 patients. 7 Among other drugs considered for repurposing, neither azithromycin, 8 Fluvoxamine's mechanism of action in COVID-19 is still unknown, but it is presumed to be multifactorial (see Figure 1 ). [15] [16] [17] Besides being an SSRI, fluvoxamine also has high affinity for the sigma-1 receptor (S1R) which has been shown to mediate fluvoxamine's antiinflammatory and immunomodulatory effects in an animal model of lipopolysaccharide (LPS) induced sepsis. 18 The same study also reported that fluvoxamine significantly reduced the production of interleukin (IL)-6, IL-1 beta, IL-12 and IL-8 induced by LPS in human heparinised peripheral blood. 18 In light of COVID-19, S1R activation is believed to act immunomodulatorily by reducing endoplasmic reticulum stress due to SARS-CoV-2 replication resulting in a reduction of proinflammatory cytokine production. 17, 19 Fluvoxamine is also known to inhibit cyclooxygenase 2 expression in LPSstimulated macrophages. 20 Additionally, fluvoxamine was also proposed as a lysosomotropic agent which, by influencing intravesical pH levels, could disrupt intracellular endolysosomal trafficking, viral fusion and thereby dissemination. 21 The lysosomotropic properties of fluvoxamine could be tightly connected with its functional inhibition of acid sphingomyelinase (FIASMA). Additional research suggested that fluvoxamine could be a FIASMA agent. 22 It seems that SARS-CoV-2 cell viral entry depends on activation of the ASM/ceramide system which leads to the formation of ceramide-enriched membrane domains and clustering of ACE2 SARS-CoV-2 viral entry receptors. 23 Inhibition of ASM by antidepressants fluoxetine and amitriptyline, which are also FIASMA agents, was shown to inhibit the entry and propagation of SARS-CoV-2 in cell culture models. 24, 25 Other suggested mechanisms possibly contributing to fluvoxamine protective effects in COVID-19 include prevention of platelet hyperreactivity and serotonin depletion, 15 increases in plasma melatonin levels through CYP1A2 and CYP2C19 inhibition 26 and inhibition of mast cell histamine release. 15 What is already known about this subject • Fluvoxamine is known to reduce inflammation and cytokine production in a mouse sepsis model through interactions with the sigma-1 receptor.

• Early outpatient treatment of COVID-19 patients with fluvoxamine has been demonstrated as effective in preventing clinical deterioration and hospitalisation in three studies performed thus far.

What this study adds Table 1 .

There were no significant differences between the groups with regard to age, gender, body mass index (BMI), chronic comorbidities, disease duration prior to ICU admission, COVID-19 vaccination status, Apache II or SOFA score.

Treatment outcomes are shown in Table 2 Complications comparison between the groups is shown in Table 3 . There were no significant differences between groups, except for CRRT, which was administered to 41.2% (n = 21/51) of fluvoxamine patients in comparison to 11.8% (n = 6/51) of standard therapy patients (P < .001).

A multivariate Cox regression analysis of time to death was conducted on time-constant covariates for all 102 patients (see Table 4 ). Concerning the protective effects of COVID-19 vaccination status on patient outcomes, only one patient in each group was fully vaccinated, while five more patients in each study arm were partially vaccinated; however, we observed no significant association between vaccination status and mortality reduction.

Looking at mortality according to gender, it seems the effect of fluvoxamine was more significant among female COVID-19 ICU patients. Gender differences in mortality in ICU COVID-19 patients have been described before, with significantly lower mortality rates among women. 28 Also, gender-specific differences in fluvoxamine pharmacokinetics have been described in the published literature, 29 as well as gender differences in CYP2D6 30 and CYP1A2 31 enzyme activity. Whether the same gender-specific differences which impact COVID-19 mortality also play a role in the response to fluvoxamine treatment, or whether biological sex-specific differences in cytochrome P450 enzymes CYP2D6 and/or CYP1A2 could be responsible for improved efficacy in female patients and consequently better outcomes remains to be investigated in additional studies.

Moreover, there were roughly 40% more diabetic women in the control arm as compared to the treatment arm. As diabetes is a wellknown poor prognostic factor in severely ill COVID-19 patients, it is possible that this fact contributed to an increased mortality among diabetic women in the control group, 80% (n = 4/5) vs 67% (n = 2/3) in the treatment arm. Importantly, univariate Cox regression analysis performed for diabetes mellitus covariate among females was not significant, HR 1.55, 95% CI (0.59 ± 4.01; P = .4), most likely due to the small sample size.

Additionally, mortality among men with coronary artery disease was 100% (n = 4/4) in the treatment as well as in the control arm (n = 2/2). It was 33% (n = 1/3) among women in the treatment group, while no women with coronary artery disease were present in the control group. History of coronary artery disease was a covariate most strongly associated with poor prognosis in this study, HR 4.06, 95%

CI (1.33 ± 12.35; P = .014) (see Table 4 ). Cox regression analysis demonstrated CRRT to be statistically significantly associated with increased mortality in our patients, HR 2.26, 95% CI (1.14 ± 4.49; P = .019) (see Table 4 ). Moreover, cytokine removal by means of CRRT remains nonselective, as both pro-and anti-inflammatory cytokines are eliminated, thereby limiting the usefulness of this treatment approach in COVID-19 patients.

Fluvoxamine also inhibits the uptake of serotonin into platelets, thus leading to an increase in bleeding risk; however, we identified no difference in the incidence of severe bleeding between the groups.

While the safety profile of fluvoxamine in ICU COVID-19 patients appears good, physicians prescribing it should be aware of possible 

Steve Kirsch (COVID-19 Early Treatment Fund), Katica Kodzoman

No funding support was provided for this study. REFERENCES 1. WHO. COVID-19 Weekly Epidemiological Update 55

Will vaccination refusal prolong the war on SARS-CoV-2?

New waves, new variants, old inequity: a continuing COVID-19 crisis

Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Repurposed antiviral drugs for Covid-19-interim WHO Solidarity Trial results

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Effect of Early Treatment with Metformin on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial

The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Flawed ivermectin preprint highlights challenges of COVID drug studies

Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial

Prospective cohort of fluvoxamine for early treatment of Coronavirus Disease 19

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Fluvoxamine: a review of its mechanism of action and its role in COVID-19

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis

Old drug fluvoxamine, new hope for COVID-19

Evaluation of the effect of antidepressant drug, fluvoxamine, on cyclooxygenase-2 protein expression in lipopolysaccharide-stimulated macrophages

Widely available lysosome targeting agents should be considered as potential therapy for COVID-19

Identification of novel functional inhibitors of acid sphingomyelinase

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells

Fluvoxamine, melatonin and COVID-19. Psychopharmacology (Berl)

The Concise Guide to PHAR-MACOLOGY 2021/22: Introduction and other protein targets

Sex differences in mortality in the intensive care unit patients with severe COVID-19

Sex differences in pharmacokinetics and pharmacodynamics

Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers

Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population

Fluvoxamine: safety profile in extensive post-marketing surveillance

Post-marketing surveillance of fluvoxamine maleate used long-term in patients with social anxiety disorder in Japan

Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data

Continuous renal replacement therapy: a review of use and application in pediatric hematopoietic stem cell transplant recipients

Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label

We would like to acknowledge the help and dedication of the following colleagues who participated in the care of our patients or have otherwise supported us in the conduct of this study: Nikola Blazevic

All authors declare no conflict of interests. Robert Likic is an executive editor of the British Journal of Clinical Pharmacology. 

The data are not publicly available due to privacy or ethical restrictions.

https://orcid.org/0000-0002-8750-2083Robert Likic https://orcid.org/0000-0003-1413-4862